Quality of live in patients with corrected iron deficiency after myocardial infarction
D.R. KHASTIEVA, N.A. TARASOVA, I.KH. VALEEVA, N.R. KHASANOV
Kazan State Medical University, Kazan
Contact details:
Khastieva D.R. — Assistant Lecturer of the Department of Introduction to Internal Diseases named after Prof. S.S. Zimnitskiy
Address: 49 Butlerov St., 420012 Kazan, Russian Federation, tel.: +7-905-020-44-07, e-mail: dilyara_khastieva@mail.ru
Iron deficiency (ID) is associated with worse quality of life and outcomes in patients with acute coronary syndrome.
The purpose — to study quality of life in patients with myocardial infarction (MI) and iron deficiency during 12 months against the background of iron supplement intake.
Material and methods. 99 patients with myocardial infarction (MI) and iron deficiency hospitalized in Kazan Clinical Hospital No. 7 were examined. The patients underwent iron deficit correction with supplements. After 3 months, the patients were divided into 2 groups: group 1 included 69 (70%) patients with corrected ID and group 2 — 30 (30%) patients with persistent ID after the treatment. Quality of life was evaluated by the Kansas City Cardiomyopathy Questionnaire (KCCQ) within 24 hours and 3, 6, 12 months after MI.
Results. The mean of KCCQ summary points in the first 24 hours after admission was 66 ± 18 in group 1 and 77 ± 14 in group 2 (p = 0.04). In group 1, the mean KCCQ scores at 3, 6 and 12 months were significantly higher than baseline (p < 0.001) (71 ± 19, 74 ± 21, and 76 ± 10, respectively). In group 2, the mean KCCQ remained unchanged 12 months after MI. Patients with compensated ID had a 27-fold higher odds of improved quality of life at 12 months after MI than patients with persisting ID (OR = 27.0; 95% CI: 3.4–211.9).
Conclusion. Corrected ID is associated with a significant improvement of quality of life in comparison with persisting ID in patients within 12 months after MI.
Key words: iron deficiency, myocardial infarction, quality of life, KCCQ.
REFERENCES
- Mareev V.Yu., Begrambekova Yu.L., Mareev Yu.V. et al. Prevalence of iron deficiency in patients with chronic heart failure in the Russian Federation. Data from an observational cross-sectional study. Data from an observational cross-sectional study. Kardiologiya, 2022, vol. 62, no. 5, pp. 4–8 (in Russ.).
- Rumyantsev G.A., Zakharova I.N., Chernov V.M. et al. Prevalence of iron deficiency conditions and factors influencing it. Meditsinskiy sovet, 2015, no. 6, pp. 62–66 (in Russ.).
- Stable coronary heart disease. Clinical guidelines 2020 / Russian Society of Cardiology. Rossiyskiy kardiologicheskiy zhurnal, 2020, vol. 25, no. 11, pp. 201–250 (in Russ.).
- Cosentino N., Campodonico J., Pontone G. Iron deficiency in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Int. J. Cardiol, 2020, vol. 300, pp. 14–19. DOI: 10.1016/j.ijcard.2019.07.083
- Meroño O., Cladellas M., Ribas-Barquet N. et al. Iron deficiency is a determinant of functional capacity and health-related quality of life 30 days after an acute coronary syndrome. Revista espanola de cardiologia, 2017, vol. 70, pp. 363–370.
- Metra M., Jankowska E., Pagnesi M. et al. Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM-AHF trial. Eur. J. Heart Fail, 2022, vol. 24 (10), pp. 1928–1939.
- Martens P., Nijst P., Verbrugge F. et al. Impact of iron deficiency on exercise capacity and outcome in heart failure with reduced, mid-range and preserved ejection fraction. Acta Cardiol, 2018, vol. 73 (2), pp. 115–123.
- Green C., Porter C., Bresnahan D. et al. Development and evaluation of the Kansas City cardiomyopathy questionnaire: A new health status measure for heart failure. J. Am. Coll. Cardiol, 2000, vol. 35, pp. 1245–1255.
- Thygesen K., Alpert J.S., Jaffe A.S. Fourth universal definition of myocardial infarction. Circulation, 2018, vol. 138 (20), pp. e618–e651. DOI: 10.1161/CIR.0000000000000617
- Ponikowski P., van Veldhuisen D., Comin-Colet J. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur. Heart J, 2015, vol. 36, pp. 657–668. DOI: 10.1093/eurheartj/ehu385
- van Veldhuisen D., Ponikowski P., van der Meer P. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation, 2017, vol. 136, pp. 1374–1383. DOI: 10.1161/CIRCULATIONAHA.117.027497
- Russian Society of Cardiology (RSCO) Chronic heart failure. Clinical guidelines 2020. Rossiyskiy kardiologicheskiy zhurnal, 2020, vol. 25, no. 11, pp. 40–83 (in Russ.). DOI: 10.15829/1560-4071-2020-4083
- Ponikowski P., van Veldhuisen D., Comin-Colet J. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur. Heart J, 2015, vol. 36, pp. 657–668. DOI: 10.1093/eurheartj/ehu385
- van Veldhuisen D., Ponikowski P., van der Meer P. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation, 2017, vol. 136, pp. 1374–1383. DOI: 10.1161/CIRCULATIONAHA.117.027497
- Jiang F., Sun Z.Z., Tang Y.T. et al. Hepcidin expression and iron parameters change in type 2 diabetic patients. Diabetes Res. Clin. Pract, 2011, vol. 93 (1), pp. 43–48.